{"pmid":32326830,"title":"Photobiomodulation and Antiviral Photodynamic Therapy as a Possible Novel Approach in COVID-19 Management.","text":["Photobiomodulation and Antiviral Photodynamic Therapy as a Possible Novel Approach in COVID-19 Management.","Photobiomodul Photomed Laser Surg","Fekrazad, Reza","32326830"],"journal":"Photobiomodul Photomed Laser Surg","authors":["Fekrazad, Reza"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32326830","week":"202017|Apr 20 - Apr 26","doi":"10.1089/photob.2020.4868","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664996914871926784,"score":8.518259,"similar":[{"pmid":32330404,"title":"Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?","text":["Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?","Photobiomodul Photomed Laser Surg","Dominguez, Angela","Velasquez, Sergio Andres","David, Mario Alejandro","32330404"],"journal":"Photobiomodul Photomed Laser Surg","authors":["Dominguez, Angela","Velasquez, Sergio Andres","David, Mario Alejandro"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330404","week":"202017|Apr 20 - Apr 26","doi":"10.1089/photob.2020.4870","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664996914779652096,"score":72.28652},{"pmid":32334502,"title":"The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID-19.","text":["The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID-19.","As a rapidly developing etiology of a global disease, the -coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical as well to address this global concern. One such avenue that may prove to be exceeding fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, and the onset of hyperinflammation, a significant disability tied to COVID-19. Furthermore, pathways that can activate mTOR may be necessary for antihepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with greater understanding of this novel pathway, new Maiese, CNR 17,3, mTOR and Antivirals, treatments against several viral infections may successfully emerge including therapy directed for SARS-CoV-2 and COVID-19.","Curr Neurovasc Res","Maiese, Kenneth","32334502"],"abstract":["As a rapidly developing etiology of a global disease, the -coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical as well to address this global concern. One such avenue that may prove to be exceeding fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, and the onset of hyperinflammation, a significant disability tied to COVID-19. Furthermore, pathways that can activate mTOR may be necessary for antihepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with greater understanding of this novel pathway, new Maiese, CNR 17,3, mTOR and Antivirals, treatments against several viral infections may successfully emerge including therapy directed for SARS-CoV-2 and COVID-19."],"journal":"Curr Neurovasc Res","authors":["Maiese, Kenneth"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32334502","week":"202018|Apr 27 - May 03","doi":"10.2174/1567202617666200425205122","keywords":["amp activated protein kinase (ampk)","akt","covid-19","sars-cov-2","angiotensin converting enzyme 2","apoptosis","autophagy","coronaviruses","cytokines","diabetes mellitus","inflammation","influenza","interferons","interleukins","mtor complex 1 (mtorc1)","mtor complex 2 (mtorc2)","macrophage inflammatory protein 1-alpha (mip-1alpha)","mechanistic target of rapamycin (mtor)","metformin","monocyte chemoattractant protein 1 (mcp-1)","oxidative stress","tumor necrosis factor-alpha","virion"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Maiese"],"_version_":1665172301950222336,"score":64.4542},{"pmid":32320592,"title":"Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.","text":["Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.","N Engl J Med","Rubin, Eric J","Baden, Lindsey R","Morrissey, Stephen","32320592"],"journal":"N Engl J Med","authors":["Rubin, Eric J","Baden, Lindsey R","Morrissey, Stephen"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320592","week":"202017|Apr 20 - Apr 26","doi":"10.1056/NEJMe2012889","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087754412034,"score":59.971325},{"pmid":32293834,"title":"Antiviral treatment of COVID-19","text":["Antiviral treatment of COVID-19","Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate courses, up to 5%-10% can have severe, potentially life threatening course, there is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be published in the next couple of months. Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational studies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they have recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other human infections.","Turk J Med Sci","Simsek Yavuz, Serap","Unal, Serhat","32293834"],"abstract":["Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate courses, up to 5%-10% can have severe, potentially life threatening course, there is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be published in the next couple of months. Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational studies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they have recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other human infections."],"journal":"Turk J Med Sci","authors":["Simsek Yavuz, Serap","Unal, Serhat"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293834","week":"202016|Apr 13 - Apr 19","doi":"10.3906/sag-2004-145","keywords":["covid-19","sars-cov-2","antiviral"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Turkey"],"countries":["Turkey"],"countries_codes":["TUR|Turkey"],"e_drugs":["nitazoxanide","remdesivir","Hydroxychloroquine","lopinavir-ritonavir drug combination","Chloroquine","Ivermectin","favipiravir"],"_version_":1664636192600096769,"score":53.854923},{"pmid":32023685,"title":"[Potential antiviral therapeutics for 2019 Novel Coronavirus].","text":["[Potential antiviral therapeutics for 2019 Novel Coronavirus].","The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-beta, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.","Zhonghua Jie He He Hu Xi Za Zhi","Li, H","Wang, Y M","Xu, J Y","Cao, B","32023685"],"abstract":["The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-beta, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Li, H","Wang, Y M","Xu, J Y","Cao, B"],"date":"2020-02-06T11:00:00Z","year":2020,"_id":"32023685","week":"20206|Feb 03 - Feb 09","doi":"10.3760/cma.j.issn.1001-0939.2020.0002","keywords":["2019 novel coronavirus","antiviral therapy","infection"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Ribavirin","Acyclovir","Oseltamivir","lopinavir-ritonavir drug combination","Ganciclovir","Zanamivir","remdesivir"],"_version_":1664640875367497729,"score":53.01093}]}